To include your compound in the COVID-19 Resource Center, submit it here.

Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone

Fred Hutchinson Cancer Research Center hired Thomas Lynch as president and director, effective next month. Lynch was CSO of Bristol-Myers Squibb Co. (NYSE:BMY). He succeeds Gary Gilliland, who announced in September his plans to

Read the full 343 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers